These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33226651)

  • 41. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
    Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry.
    Cañete F; Mañosa M; Casanova MJ; González-Sueyro RC; Barrio J; Bermejo F; Nos P; Iglesias-Flores E; García-Planella E; Pérez-Calle JL; Vicente R; Vera M; Ramos L; Rivero M; De Francisco R; Montserrat A; Benítez O; Navarro P; Taxonera C; Hinojosa E; Márquez-Mosquera L; Navarro-Llavat M; Ramírez-de la Piscina P; Gomollón F; Rodríguez-Alonso L; Núñez-Alonso A; Fernández-Salazar L; Almela P; Ríos León R; De Castro L; Gisbert JP; Ricart E; Cabré E; Domènech E;
    Inflamm Bowel Dis; 2019 Oct; 25(11):1862-1870. PubMed ID: 31006801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease.
    Yoshihara T; Shinzaki S; Kawai S; Fujii H; Iwatani S; Yamaguchi T; Araki M; Hiyama S; Inoue T; Hayashi Y; Watabe K; Iijima H; Takehara T
    Inflamm Bowel Dis; 2017 Dec; 23(12):2172-2179. PubMed ID: 28945638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis.
    Hwang J; Kim HM; Jeong H; Lee J; Ahn JK; Koh EM; Kang ES; Cha HS
    Rev Bras Reumatol Engl Ed; 2017; 57(4):311-319. PubMed ID: 28743358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis.
    Bellur S; McHarg M; Kongwattananon W; Vitale S; Sen HN; Kodati S
    JAMA Ophthalmol; 2023 Feb; 141(2):150-156. PubMed ID: 36547953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
    Beilman CL; Kirwin E; Ma C; McCabe C; Fedorak RN; Halloran B
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1515-1524.e4. PubMed ID: 30056180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
    Chanchlani N; Lin S; Chee D; Hamilton B; Nice R; Arkir Z; Bewshea C; Cipriano B; Derikx LAAP; Dunlop A; Greathead L; Griffiths RL; Ibraheim H; Kelleher P; Kok KB; Lees CW; MacDonald J; Sebastian S; Smith PJ; McDonald TJ; Irving PM; Powell N; Kennedy NA; Goodhand JR; Ahmad T
    J Crohns Colitis; 2022 Mar; 16(3):389-397. PubMed ID: 34473254
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.
    Gorovits B; Baltrukonis DJ; Bhattacharya I; Birchler MA; Finco D; Sikkema D; Vincent MS; Lula S; Marshall L; Hickling TP
    Clin Exp Immunol; 2018 Jun; 192(3):348-365. PubMed ID: 29431871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.
    Algaba A; Linares PM; Encarnación Fernández-Contreras M; Figuerola A; Calvet X; Guerra I; de Pousa I; Chaparro M; Gisbert JP; Bermejo F
    Inflamm Bowel Dis; 2014 Apr; 20(4):695-702. PubMed ID: 24562175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Aliment Pharmacol Ther; 2018 Mar; 47(5):596-604. PubMed ID: 29239001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of a concomitant elemental diet with maintenance anti-tumor necrosis factor-α antibody therapy in patients with Crohn's disease: A multicenter, prospective cohort study.
    Hirai F; Ishida T; Takeshima F; Yamamoto S; Yoshikawa I; Ashizuka S; Inatsu H; Mitsuyama K; Sou S; Iwakiri R; Nozaki R; Ohi H; Esaki M; Iida M; Matsui T;
    J Gastroenterol Hepatol; 2019 Jan; 34(1):132-139. PubMed ID: 29935082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.